Yatiri Bio

Yatiri Bio is a private, pre-clinical stage biotech leveraging a proprietary platform integrating proteomics and deep learning to revolutionize oncology and immunology drug development. The company focuses on identifying novel therapeutic targets and creating predictive signatures for patient selection to improve clinical trial success rates and accelerate the path to market. Founded by a team of seasoned pharmaceutical veterans from companies like Celgene, Yatiri Bio is positioned to address the industry's high costs and low success rates by shifting the focus from genetic to protein-level data. While currently pre-revenue, its platform approach and experienced leadership present a significant opportunity to create value through partnerships and internal pipeline development.

Integrated platform combining advanced proteomics, bioinformatics, and deep learning to analyze patient protein data, identify therapeutic targets, and develop predictive signatures for patient selection and response prediction in drug development.

Yatiri Bio competes in the crowded AI/ML drug discovery sector with companies like Recursion, Exscientia, and Insitro, as well as internal pharma initiatives. Its differentiation is a focused emphasis on proteomic data over genomic data, but it must prove this offers a decisive advantage in predicting clinical outcomes.